In summary, our data demonstrate for the first time that IR is a novel substrate for BACE1 and that therapies targeting BACE1 inhibition could be an innovative treatment for diabetes and other diseases characterized by insulin resistance. This evidence concerns the gene BACE1 and diabetes mellitus.